Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Brief Summary: Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy


Options:
A: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: nab-Paclitaxel, Drug: Gemcitabine | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: nab-Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: nab-Paclitaxel; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm B
C: Arm Label: EC-T; Type: ACTIVE_COMPARATOR; Interventions: Drug: EC-T | Arm Label: TP; Type: EXPERIMENTAL; Interventions: Drug: TP | Intervention Type: DRUG; Name: EC-T; Assigned to Arm(s): EC-T | Intervention Type: DRUG; Name: TP; Assigned to Arm(s): TP
D: Arm Label: Arm I (paclitaxel, doxorubicin, cyclophosphamide); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel | Arm Label: Arm II (paclitaxel, ddAC, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel | Arm Label: Arm III (paclitaxel, ddAC, carboplatin); Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel | Arm Label: Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (paclitaxel, ddAC, bevacizumab), Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm III (paclitaxel, ddAC, carboplatin), Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm I (paclitaxel, doxorubicin, cyclophosphamide), Arm II (paclitaxel, ddAC, bevacizumab), Arm III (paclitaxel, ddAC, carboplatin), Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (paclitaxel, doxorubicin, cyclophosphamide), Arm II (paclitaxel, ddAC, bevacizumab), Arm III (paclitaxel, ddAC, carboplatin), Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (paclitaxel, doxorubicin, cyclophosphamide), Arm II (paclitaxel, ddAC, bevacizumab), Arm III (paclitaxel, ddAC, carboplatin), Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (paclitaxel, doxorubicin, cyclophosphamide), Arm II (paclitaxel, ddAC, bevacizumab), Arm III (paclitaxel, ddAC, carboplatin), Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin)

Answer: A